Sustained Virologic Response in Patients With Chronic Hepatitis C and Liver Cancer
In Hong Kong, researchers found data from 49 studies that were conducted in 15 countries in patients with chronic hepatitis C and hepatocellular carcinoma (HCC) or without HCC, which showed that overall, the sustained virologic response rate for direct-acting antiviral therapy was approximately 90%. In addition, they found that in patients with HCC who were treated with any sofosbuvir-based regimen had lower sustained viral response rates than the sustained viral response rates of patients without HCC who were treated with sofosbuvir-based regimens.